| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-10-20 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twenty-week review a week after the sixth and last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. [S]
Mrs. Lovelace returns a week after her sixth and last cycle of carboplatin and paclitaxel; pembrolizumab continues every three weeks. She has had no bleeding. Her average pain is 2 of 10, and she has used a breakthrough dose only twice in the past month. She would like to take less morphine. The tingling in her toes is unchanged. She feels a little more tired than usual but has no cold intolerance, constipation beyond her usual, weight gain, or palpitations. Her mood is better and she is working on new mathematical notes most mornings. [S]
| Element | Detail |
|---|---|
| Treatment | Six cycles completed; pembrolizumab continues |
| Pain | Average 2 of 10; two breakthrough doses in a month |
| Neuropathy | Mild, unchanged |
| Thyroid symptoms | Slightly more tired; no cold intolerance or weight gain |
| Work | New mathematical notes most mornings |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | A little more tired; weight steady |
| Endocrine | Negative | No cold intolerance, hair or skin change beyond chemotherapy, or palpitations |
| Neurological | Positive | Mild toe tingling, unchanged |
| Psychiatric | Negative | Mood better; PHQ-9 5 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stop | once at night for two weeks, then stop | Oral route | 2026-10-20 | active | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 2026-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-20 | Body height | 165 | cm | S |
| 2026-10-20 | Body weight | 54.4 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 78 | /min | S |
| 2026-10-20 | Respiratory rate | 16 | /min | S |
| 2026-10-20 | Body temperature | 36.6 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-20 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-10-20 | Leukocytes [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-20 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-10-20 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 2026-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-10-20 | Thyrotropin [Units/volume] in Serum or Plasma | 7.8 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-10-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-10-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-10-20 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, alert; blood pressure 114/72, pulse 78, weight 54.4 kg |
| Neck | No thyroid enlargement or tenderness |
| Neurological | Reflexes normal; grade 1 sensory neuropathy at the toes |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 10.9 g/dL, white cells 4.2, neutrophils 2.4, platelets 188 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.71 mg/dL, eGFR 114, ALT 24 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Completed today | TSH 7.8 mIU/L, free T4 1.0 ng/dL, six weeks after the last check; subclinical; repeat in six weeks |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | Mild tiredness only |
| Examination | Peripheral neuropathy on paclitaxel | With taxane treatment and after | Completed today | Grade 1, unchanged |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Due | About three months after the last CT, in six weeks |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 2 of 10 |
| Medication safety | Opioid taper when pain improves | When pain is controlled after treatment | Completed today | Long-acting morphine reduced to nightly for two weeks, then stopped |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Regular |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change | Completed today | Naloxone in date; take-back advised |
| Survey | Depression screen (PHQ-9) and distress | Periodically | Completed today | PHQ-9 5 |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Up to date | Monthly palliative care visits |
| Self-management | Goals-of-care conversation | At each restaging | Up to date | Recorded six weeks ago; to revisit after the next CT |
Goal progress:
Immunizations given today: Influenza vaccine, inactivated, trivalent; COVID-19 mRNA vaccine, current season; Recombinant zoster vaccine, dose 2 of 2; Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (Dowell D, et al. MMWR Recomm Rep 2022;71(RR-3):1-95) (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)
Follow-up: Telephone check in one week. Review after the restaging CT in about six weeks. [S]